Checchi Capital Advisers LLC Has $325,000 Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Checchi Capital Advisers LLC boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,656 shares of the medical research company’s stock after acquiring an additional 137 shares during the period. Checchi Capital Advisers LLC’s holdings in IQVIA were worth $325,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the third quarter worth about $27,000. Synergy Asset Management LLC acquired a new stake in IQVIA in the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC increased its position in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the period. Assetmark Inc. boosted its position in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in shares of IQVIA in the third quarter worth $57,000. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares in the company, valued at $255,739.50. This represents a ? increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Down 2.4 %

IQV opened at $186.40 on Friday. IQVIA Holdings Inc. has a twelve month low of $184.66 and a twelve month high of $261.73. The firm has a market cap of $32.82 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 1.99 and a beta of 1.48. The firm’s 50-day simple moving average is $199.30 and its 200-day simple moving average is $215.26. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

IQV has been the subject of a number of research reports. The Goldman Sachs Group reduced their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Barclays reduced their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Robert W. Baird lowered their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft reduced their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Stifel Nicolaus lowered their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.